Innovative Substance Repurposing
Through novel galenic platform technologies, we develop cutting edge  nutraceutical and pharmaceutical products.
Learn More
Our Mission
Empower people to perform every day at their best – from the very moment they wake up.
products

Nutraceuticals

Our first nutraceutical product is for those who seek to control their inner clock and wake up with ease. Unlike other sleep-aids or your alarm clock, it empowers night owls, shift workers and business travelers to control their wake-up process.

Learn More
Our first nutraceutical product is for those who seek to control their inner clock and wake up with ease. Unlike other sleep-aids or your alarm clock, it empowers night owls, shift workers and business travelers to control their wake-up process.
Products

Pharmaceuticals

Most of the current sleep medications show unsatisfactory clinical efficacy and can cause several side effects. We have found an API that has highly potent sleep consolidating properties when combined with an innovative galenic formulation.

Learn More
Most of the current sleep medications show unsatisfactory clinical efficacy and can cause several side effects. We have found an API that has highly potent sleep consolidating properties when combined with an innovative galenic formulation.
About Us

Who we are

Founded in 2018 in Switzerland, we are on a mission to empower people around the globe, to perform at their very best, from the moment they wake up.

Learn More
Galventa Founders Dario Dornbierer and Sascha Fritsche
About Us

Latest news

Galventa wins CHF 150'000 funding from Venture Kick
January 28, 2022

The St. Gallen-based Galventa AG, wins the final stage of Venture Kick. The funding will contribute to advancing the development of Galventa’s product portfolio and launching B • SYNC ON in different markets.

Read more
Galventa closes CHF 750k seed round for world’s first nutraceutical supplement
October 4, 2021

The Swiss life science startup behind the first nutraceutical supplement to control the wake-up process, has secured a CHF 750,000 seed investment.

Read more
Galventa AG signs an investment Agreement with Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş.
August 19, 2021

We are pleased to announce that Galventa AG has signed an investment agreement with Gen, which is a leading Turkish pharmaceutical company

Read more